⌕
Edgewise Therapeutics · EWTX · Nasdaq
Tenet 69 · Solid
Compare
$43.68−4.90%At closeTenet 69 · Solid
$43.68−2.25 (−4.90%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Edgewise Therapeutics (EWTX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+174.3%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼25.4%
−167.8
FY21→FY25CAGR —
Free cash flow ($M)▼30.6%
−144.1
FY21→FY25CAGR —
Diluted EPS▼12.4%
−1.63
no value for 2 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+174.3%

37.5mn → 102.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$256.0K

−80.5% YoY in FY25.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−151.4R&D−40.0SG&A−191.4Op income23.6Tax & other−167.8Net income

Margin trend · direction beats level
108530%sector median net margin ~4%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
165,368.0151,389.0126,966.090,905.054,032.032,189.0▲19.2%+47.3%
Selling, general & admin
52,812.040,017.031,866.023,452.017,626.011,026.0▲25.6%+38.0%
Total operating expenses
218,180.0191,406.0158,832.0114,357.071,658.043,215.0▲20.5%+45.1%
Operating incomefeeds ROC rank
−218,180.0−191,406.0−158,832.0−114,357.0−71,658.0−43,215.0▼20.5%—
Other income, net
1,383,108.023,611.025,019.014,194.04,018.0402.0——
Pretax income
1,164,928.0−167,795.0−133,813.0−100,163.0−67,640.0−42,813.0▼25.4%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
1,009,595.0−167,795.0−133,813.0−100,163.0−67,640.0−42,813.0▼25.4%—
Per share
Diluted EPSbuyback-sensitive
8.19−1.63−1.45−1.57——▼12.4%—
Diluted shares (mn)
120.87102.9392.4163.7253.5937.53▲11.4%+28.7%
Margins
† TTM = trailing four quarters through 2026-09-30.
FY20 – FY20 · 1 more year
Unlock the full history →
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.